Abstract:In this study, we use primary neuronal cultures from two mouse models carrying pathogenic variants in the SCN2A sodium channel to assess their impact on neuronal network activity. Using multielectrode array analysis, we show that the two variants, R1882Q and R853Q, which cause distinctive clinical phenotype of severe childhood epilepsy and opposing effects on channel biophysical properties, alter network parameters, and respond to antiepileptic drugs in different ways. We conclude that this type of analysis may be useful for disease modeling and drug screening. De novo variants in the NaV1.2 voltage‐gated sodium channel gene SCN2A are among the major causes of developmental and epileptic encephalopathies (DEE). Based on their biophysical impact on channel conductance and gating, SCN2A DEE variants can be classified into gain‐of‐function (GoF) or loss‐of‐function (LoF). Clinical and functional data have linked early seizure onset DEE to the GoF SCN2A variants, whereas late seizure onset DEE is associated with the loss of SCN2A function. This study aims to assess the impact of GoF and LoF SCN2A variants on cultured neuronal network activity and explore their modulation by selected antiseizure medications (ASM). To this end, primary cortical cultures were generated from two knock‐in mouse lines carrying variants corresponding to human GoF SCN2A p.R1882Q and LoF p.R853Q DEE variant. In vitro neuronal network activity and responses to ASM were analyzed using multielectrode array (MEA) between 2 and 4 weeks in culture. The SCN2A p.R1882Q neuronal cultures showed significantly greater mean firing and burst firing. Their network synchronicity was also higher. In contrast, the SCN2A p.R853Q cultures showed lower mean firing rate, and burst firing events were less frequent. The network synchronicity was also lower. Phenytoin and levetiracetam reduced the excitability of GoF cultures, while retigabine showed differential and potentially beneficial effects on cultures with both GoF and LoF variants. We conclude that in vitro neuronal networks harboring SCN2A GoF or LoF DEE variants present with distinctive phenotypes and responses to ASM.

An iPSC line (FINi003-A) from a male with late-onset developmental and epileptic encephalopathy caused by a heterozygous p.E1211K variant in the SCN2A gene encoding the voltage-gated sodium channel Na v 1.2

Generation of three induced pluripotent stem cell lines from a patient with KCNQ2 developmental and epileptic encephalopathy as a result of the pathogenic variant c.881C > T; p.Ala294Val (NUIGi059-A, NUIGi059-B, NUIGi059-C) and 3 healthy controls (NUIGi060-A, NUIGi060-B, NUIGi060-C)

Generation of an Induced Pluripotent Stem Cell Line (FDCHI007-A) Derived from a Patient with Developmental and Epileptic Encephalopathy Type 31 Carrying Heterozygous C.545c > A Mutation in DNM1 Gene

Generation of an Induced Pluripotent Stem Cell Line from a Brugada Syndrome Patient Carrying SCN5A/c.3118G>C Mutation

Generation of a Human Induced Pluripotent Stem Cell Line (Cipi002-A) from an Early Infantile Epileptic Encephalopathy Patient with a Heterozygous Mutation in SCN8A

Generation of a Human Ipsc Line (Zjshdpi001-A) from Peripheral Blood Mononuclear Cells of a Patient with Developmental Epileptic Encephalopathy-47 Carrying FGF12 Gene Mutation (c.334g > A)

Generation of induced pluripotent stem cell line, NIMHi013-A, from PBMCs of a female child with epilepsy carrying a novel SCN1A variant

Electrophysiological Features: the Next Precise Step for SCN2A Developmental Epileptic Encephalopathy

A Heterozygous SCN1A (c.a5768g/+) Mutant Human Induced Pluripotent Stem Cell Line (Ustci002-A) Generated Using TALEN-mediated Precise Gene Editing

Emerging neurodevelopmental mechanisms in patient induced pluripotent stem cells-derived spheroids modelling SCN1A Dravet Syndrome

Derivation of an induced pluripotent stem cell line (FDCHi014-A) from PBMCs of a seven-year-old patient with a truncating NOVA2 variant (c.625del)

Generation of a Human Ipsc Line CIPi003-A from a Patient with Focal Epilepsy Harboring a Heterozygous Mutation in DEPDC5 Gene.

Leveraging multiple approaches for the detection of pathogenic deep intronic variants in developmental and epileptic encephalopathies: A case report

Generation of three induced pluripotent stem cell lines from a patient with KCNQ2 developmental and epileptic encephalopathy as a result of the pathogenic variant c.638C > T; p.Arg213Gln (NUIGi063-A, NUIGi063-B, NUIGi063-C) and 3 healthy controls (NUIGi064-A, NUIGi064-B, NUIGi064-C)

An induced pluripotent stem cell line (EHTJUi004-A) generated from a neonate with c.4683_4684delCT:p.Leu1563fs mutation in the gene <i>DSP</i> causing Familial Arrhythmogenic Right Ventricular Dysplasia (ARVD)

Induced Pluripotent Stem Cell (iPSC) Lines from a Family with Resistant Epileptic Encephalopathy Caused by Compound Heterozygous Mutations in SZT2 Gene

Establishment Of An Induced Pluripotent Stem Cell Line (Zjshi001-A) From A Patient With Epileptic Encephalopathy Carrying Kcnb1 Glu330asp Mutation

Variant‐specific in vitro neuronal network phenotypes and drug sensitivity in SCN2A developmental and epileptic encephalopathy

Induced pluripotent stem cells (SHCDNi006-A cells) isolated from the peripheral blood mononuclear cells of a five-month-old Chinese girl with the heterozygous missense mutation (c.2800 G>A) in the KCNT1 gene

Allele‐Specific Editing of a Dominant SCN8A Epilepsy Variant Protects against Seizures and Lethality in a Murine Model

A SCN8A variant associated with severe early onset epilepsy and developmental delay: Loss- or gain-of-function?